drugset
drugset / Trial / NCT00702975

Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy

NCT00702975 ↗

Phase 2 Completed 35 enrolled Radboud University Medical Center
NaSingle-groupOpen-labelTreatment

Summary

A phase II study of combination therapy of carboplatin -gemcitabine plus bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) who have not received prior chemotherapy.

Timeline

Start
2008-09
Primary completion
2013-02
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 15 mg/kg Intravenous
Subject Carboplatin Small molecule — —
Subject Erlotinib Small molecule 150 mg Oral
Subject Paclitaxel Small molecule 200 mg/m2 —

Indications

non-small cell lung carcinoma